Loading organizations...
Lauxera Capital Partners is an independent, international investment fund focused on growth-stage Healthtech companies. The firm invests in businesses with significant revenue and early profitability, providing capital, operational expertise, and a robust growth framework. Their objective is to accelerate market adoption of Healthtech innovations across global markets.
The company was founded in 2020 by Samuel Levy, Pierre Moustial, and Alex Slack. These experienced entrepreneurs and investors established Lauxera to combine operational insights with investment strategy. Pierre Moustial brings executive leadership from major pharmaceutical groups; Samuel Levy co-founded a Healthtech company, informing their specific approach.
Lauxera partners directly with Healthtech management teams and founders, assisting with commercialization strategies and market optimization. The firm’s vision is to accelerate widespread adoption of Healthtech innovations. Through strategic support and capital, Lauxera aims to enhance healthcare system efficiency, ultimately improving human health outcomes globally.
Key people at Lauxera Capital Partners.
Lauxera Capital Partners was founded in 2020 by Alex Slack (Co-Founder).
Key people at Lauxera Capital Partners.
Lauxera Capital Partners is a transatlantic investment firm founded in 2020, headquartered in Paris with an office in San Francisco, specializing in growth-stage investments in healthtech, life sciences, medical devices, digital health, technology-enabled services, life science tools, diagnostics, and healthcare IT.[1][2][3][4] The firm's mission is to transform Europe's promising healthtech pioneers into global leaders by providing capital, operational expertise, and transatlantic support to scale commercially de-risked companies addressing large markets (€500m+).[1][2][4] With over €600 million in assets under management across 13 portfolio companies, Lauxera emphasizes hands-on partnership to drive organic growth, international expansion (especially into the US), regulatory navigation, and impact for patients and healthcare systems via its "Carried for Interest" program.[2][3]
Its investment philosophy prioritizes scientifically validated, revenue-generating businesses led by world-class managers, combining 50 years of healthcare investing experience and 35 years of scaling healthcare companies to improve efficiency, save lives, and reduce costs.[1][3][4] Lauxera significantly impacts the startup ecosystem by bridging European innovation with US market access, offering strategic guidance, talent management, and a growth toolbox that accelerates commercialization and external opportunities, as seen in its €50m investment in Acandis for stroke prevention devices.[2]
Lauxera Capital Partners was established in 2020 by entrepreneurial company builders and seasoned healthcare investors with deep operational roots in Europe and global expertise.[1][2][4][6] Key founding partner Alex Slack, based in Mill Valley, US, leads alongside a Paris-based team including Principal Charles Cornevin, CFO Anna Yang, and Investor Relations Manager Alix De Benedetti.[6] The firm emerged to address gaps in traditional European private equity by adopting a hands-on, operator-led model, drawing from decades of experience in building commercial organizations, mentoring teams, and navigating healthcare growth stages.[1][3][4]
Its evolution has focused sharply on healthtech since inception, rapidly scaling to manage over €600m and support 13 companies, with two funds closed by February 2022 and October 2025.[2][6][7] Pivotal early moves include investments like the January 2025 €50m commitment to Acandis, highlighting Lauxera's ability to attract partners valuing its US links, medical device expertise, and agile growth support.[2]
Lauxera rides the global healthtech boom, fueled by aging populations, post-pandemic digital adoption, and demand for cost-efficient care amid €500m+ addressable markets in devices, diagnostics, and IT.[1][3][4] Timing is ideal: scientific de-risking and revenue visibility in growth-stage firms align with maturing ecosystems, while US expansion counters Europe's scale limitations.[1][2] Market forces like regulatory convergence, AI-driven tools, and M&A activity favor its model, as seen in Acandis' US trials push.[2]
The firm influences the ecosystem by elevating European healthtech to global competitiveness, fostering transatlantic flows that attract follow-on capital and talent, and prioritizing patient outcomes to build sustainable franchises.[1][2][4]
Lauxera is poised for accelerated growth with recent fund closes and a €600m+ war chest, likely targeting more Series B/C healthtech deals in AI diagnostics, neurovascular tech, and data platforms amid rising US-Europe synergies.[2][3][6] Trends like personalized medicine, regulatory streamlining, and healthcare digitization will amplify its edge, potentially doubling AUM as portfolio exits materialize.[1][4] Its influence may evolve toward larger platforms and impact funds, solidifying as Europe's go-to healthtech scaler—transforming pioneers into leaders as envisioned from day one.[1][2]
